Related references
Note: Only part of the references are listed.IncreasedABCC2expression predicts cisplatin resistance in non-small cell lung cancer
Yun Chen et al.
CELL BIOCHEMISTRY AND FUNCTION (2021)
Monocarboxylate Transporter 6-Mediated Interactions with Prostaglandin F-2 alpha: In Vitro and In Vivo Evidence Utilizing a Knockout Mouse Model
Robert S. Jones et al.
PHARMACEUTICS (2020)
A phase Ib adaptive study of dasatinib for the prevention of oxaliplatin-induced neuropathy in patients with metastatic colorectal cancer receiving FOLFOX chemotherapy and bevacizumab.
Anne M. Noonan et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice
Kevin M. Huang et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study
Thorsten Langer et al.
EUROPEAN JOURNAL OF CANCER (2020)
Prevention of cisplatin-induced ototoxicity in children and adolescents with cancer: a clinical practice guideline
David R. Freyer et al.
LANCET CHILD & ADOLESCENT HEALTH (2020)
Interventions for cisplatin-induced hearing loss in children and adolescents with cancer
David R. Freyer et al.
LANCET CHILD & ADOLESCENT HEALTH (2019)
The genetic vulnerability to cisplatin ototoxicity: a systematic review
Evangelia Tserga et al.
SCIENTIFIC REPORTS (2019)
Clinical and Functional Relevance of the Monocarboxylate Transporter Family in Disease Pathophysiology and Drug Therapy
Pascale Fisel et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity
Tom T. G. Nieskens et al.
DRUG METABOLISM AND DISPOSITION (2018)
CDK2 inhibitors as candidate therapeutics for cisplatin-and noise-induced hearing loss
Tal Teitz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
Pantoprazole, an Inhibitor of the Organic Cation Transporter 2, Does Not Ameliorate Cisplatin-Related Ototoxicity or Nephrotoxicity in Children and Adolescents with Newly Diagnosed Osteosarcoma Treated with Methotrexate, Doxorubicin, and Cisplatin
Elizabeth Fox et al.
ONCOLOGIST (2018)
Association between genetic polymorphisms and platinum-induced ototoxicity in children
Gabrielle Lui et al.
Oncotarget (2018)
The selective tyrosine kinase-inhibitor nilotinib alleviates experimentally induced cisplatin nephrotoxicity and heptotoxicity
Hayam Ateyya et al.
ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY (2017)
A Systematic Review of Strategies to Prevent Cisplatin-Induced Nephrotoxicity
Daniel J. Crona et al.
ONCOLOGIST (2017)
Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer
Britt I. Drogemoller et al.
JAMA ONCOLOGY (2017)
Drug Delivery Strategies for Platinum-Based Chemotherapy
Richard J. Browning et al.
ACS NANO (2017)
Identification of OAT1/OAT3 as Contributors to Cisplatin Toxicity
S. Hu et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2017)
ABCB1 and ABCG2 drug transporters are differentially expressed in non-small cell lung cancers (NSCLC) and expression is modified by cisplatin treatment via altered Wnt signaling
M. Vesel et al.
RESPIRATORY RESEARCH (2017)
Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine
Anne T. Nies et al.
ARCHIVES OF TOXICOLOGY (2016)
Inhibition of OCT2, MATE1 and MATE2-K as a possible mechanism of drug interaction between pazopanib and cisplatin
C. Sauzay et al.
PHARMACOLOGICAL RESEARCH (2016)
A phosphotyrosine switch regulates organic cation transporters
Jason A. Sprowl et al.
NATURE COMMUNICATIONS (2016)
Cisplatin-Associated Ototoxicity: A Review for the Health Professional
Jessica Paken et al.
JOURNAL OF TOXICOLOGY (2016)
Handling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters
Sanjay K. Nigam et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions
Navjotsingh Pabla et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Role of transporters in the distribution of platinum-based drugs
Saliha Harrach et al.
FRONTIERS IN PHARMACOLOGY (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
What do drug transporters really do?
Sanjay K. Nigam
NATURE REVIEWS DRUG DISCOVERY (2015)
Substrate-Dependent Inhibition of the Human Organic Cation Transporter OCT2: A Comparison of Metformin with Experimental Substrates
Kristina Hacker et al.
PLOS ONE (2015)
Mechanism of Cisplatin-Induced Cytotoxicity Is Correlated to Impaired Metabolism Due to Mitochondrial ROS Generation
Yong-Min Choi et al.
PLOS ONE (2015)
Transgenic Expression of the Human MRP2 Transporter Reduces Cisplatin Accumulation and Nephrotoxicity in Mrp2-Null Mice
Xia Wen et al.
AMERICAN JOURNAL OF PATHOLOGY (2014)
Cisplatin-Induced Renal Injury Is Independently Mediated by OCT2 and p53
Jason A. Sprowl et al.
CLINICAL CANCER RESEARCH (2014)
Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo
Xiao-kun Wang et al.
ONCOTARGET (2014)
An Src-protein tyrosine kinase inhibitor to reduce cisplatin ototoxicity while preserving its antitumor effect
Eric C. Bielefeld et al.
ANTI-CANCER DRUGS (2013)
Replication of TPMT and ABCC3 Genetic Variants Highly Associated With Cisplatin-Induced Hearing Loss in Children
K. Pussegoda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance
J. A. Sprowl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2013)
Cisplatin and Radiotherapy With or Without Erlotinib in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomized Phase II Trial
Renato G. Martins et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Oxaliplatin-induced neurotoxicity is dependent on the organic cation transporter OCT2
Jason A. Sprowl et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Understanding platinum-induced ototoxicity
Thorsten Langer et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients
Xiaojing Xu et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2012)
Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy
J. A. Sprowl et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer chemotherapy response and prognosis
Daniele Campa et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients
Xiaojing Xu et al.
LUNG CANCER (2012)
Cisplatin ototoxicity in rat cochlear organotypic cultures
Dalian Ding et al.
HEARING RESEARCH (2011)
Copper Transporter 2 Regulates Endocytosis and Controls Tumor Growth and Sensitivity to Cisplatin In Vivo
Brian G. Blair et al.
MOLECULAR PHARMACOLOGY (2011)
Proton Pump Inhibitors Inhibit Metformin Uptake by Organic Cation Transporters (OCTs)
Anne T. Nies et al.
PLOS ONE (2011)
Organic Cation Transporter 2 Mediates Cisplatin-Induced Oto- and Nephrotoxicity and Is a Target for Protective Interventions
Giuliano Ciarimboli et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Genetic variation in glutathione metabolism and DNA repair genes predicts survival of small-cell lung cancer patients
Z. Sun et al.
ANNALS OF ONCOLOGY (2010)
Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity
Takanori Nakamura et al.
BIOCHEMICAL PHARMACOLOGY (2010)
Protecting Cisplatin-Induced Nephrotoxicity with Cimetidine Does Not Affect Antitumor Activity
Hiromu Katsuda et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2010)
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Seiko Ishida et al.
CANCER CELL (2010)
Influence of Oct1/Oct2-Deficiency on Cisplatin-Induced Changes in Urinary N-Acetyl-β-D-Glucosaminidase
Ryan M. Franke et al.
CLINICAL CANCER RESEARCH (2010)
Role of the Copper Transporter, CTR1, in Platinum-Induced Ototoxicity
Swati S. More et al.
JOURNAL OF NEUROSCIENCE (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Cellular Responses to Cisplatin-Induced DNA Damage
Alakananda Basu et al.
JOURNAL OF NUCLEIC ACIDS (2010)
Copper Transporter 2 Regulates the Cellular Accumulation and Cytotoxicity of Cisplatin and Carboplatin
Brian G. Blair et al.
CLINICAL CANCER RESEARCH (2009)
Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity
K. K. Filipski et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2009)
Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population
Ji-Ye Yin et al.
PHARMACOGENETICS AND GENOMICS (2009)
The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity
Navjotsingh Pabla et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2009)
Interaction of cisplatin with the human organic cation transporter 2
Kelly K. Filipski et al.
CLINICAL CANCER RESEARCH (2008)
Hearing loss, quality of life, and academic problems in long-term neuroblastoma survivors: Report from the Children's Oncology Group
James G. Gurney et al.
PEDIATRICS (2007)
Apoptosis by cisplatin requires p53 mediated p38α MAPK activation through ROS generation
Paloma Bragado et al.
APOPTOSIS (2007)
Molecular mechanisms of resistance and toxicity associated with platinating agents
Cara A. Rabik et al.
CANCER TREATMENT REVIEWS (2007)
Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition
Gabriele Jedlitschky et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2006)
Functional characterization of human monocarboxylate transporter 6 (SLC16A5)
Y Murakami et al.
DRUG METABOLISM AND DISPOSITION (2005)
Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2
G Ciarimboli et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
The copper influx transporter human copper transport protein 1 regulates the uptake of cisplatin in human ovarian carcinoma cells
AK Holzer et al.
MOLECULAR PHARMACOLOGY (2004)
Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B
G Samimi et al.
MOLECULAR PHARMACOLOGY (2004)
Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers
M Markman et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2004)
High pressure liquid chromatography and mass spectrometry characterization of the nephrotoxic biotransformation products of cisplatin
DM Townsend et al.
DRUG METABOLISM AND DISPOSITION (2003)
Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients
FE de Jongh et al.
BRITISH JOURNAL OF CANCER (2003)
Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity
MJ van den Bent et al.
EUROPEAN JOURNAL OF CANCER (2002)
Share Paper
